Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s Emms takes up ABPI presidency

He succeeds MSD’s Deepak Khanna at the UK pharma industry body

Jonathan Emms, ABPIPfizer's UK managing director Jonathan Emms has taken up the role of president of the Association of the British Pharmaceutical Industry (ABPI).

Emms (pictured right) was elected to the position at the pharma industry body in December 2013 and will now serve for one year with the option of standing for re-election.

He takes over from MSD's Deepak Khanna who spent two years as president, working alongside CEO Stephen Whitehead to improve the image of the industry in the UK and represent its companies in issues such as the value-based pricing debate and the implementation of a new NHS commissioning system in England.

Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK.

He has not been afraid to criticise the outcomes of these discussions too, saying in November that the revised drug pricing scheme announced by the Department of Health was a “missed opportunity for British patients, the UK economy and industry”.

These concerns about access to new medicines were reiterated by Emms in a statement on what he hopes to achieve in his new role.

“High barriers to getting innovative medicines to patients and low and slow usage across the NHS means we risk falling behind our European neighbours. As president, I want to tackle the challenges head on and work together – industry, government and NHS – to make change happen.”

14th April 2014

From: Research, Sales, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....